AI-generated summary
This narrative review synthesizes evidence on how disrupted circadian rhythms relate to major depressive disorder, drawing on genetic, clinical and therapeutic studies. The authors report that patients show altered sleep-wake cycles, diurnal mood patterns and metabolic functions, and that variants in clock genes such as CLOCK, TIMELESS and CRY1 correlate with both circadian disruption and depression susceptibility. They suggest circadian dysfunction may be causal rather than merely symptomatic, and that chronotherapeutic approaches show potential, though these claims are not quantified in the abstract.
- Who or what was studied
- Patients with major depressive disorder
- Limits stated in the abstract
- The abstract does not report the number of studies reviewed, and the review describes potential rather than demonstrated benefit of the proposed therapies.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Major Depressive Disorder (MDD) has emerged as a leading cause of disability worldwide, affecting over 264 million people. Recent evidence reveals that disruption of circadian rhythms may be fundamental to MDD pathophysiology, opening new avenues for therapeutic intervention.
Methods
This review synthesizes current understanding of the intricate relationship between circadian system disruption and MDD, highlighting molecular mechanisms and clinical implications. We examine evidence from genetic studies, clinical observations, and therapeutic trials.
Results
Patients with MDD exhibit profound alterations in circadian-regulated processes, including sleep-wake cycles, diurnal mood patterns, and metabolic functions. Genetic studies have identified variants in core clock genes, particularly CLOCK, TIMELESS, and CRY1, that correlate with both circadian disruption and MDD susceptibility. These genetic insights, combined with evidence of dysregulated hypothalamus-pituitary-adrenal axis function and abnormal melatonin signaling, suggest that circadian dysfunction may be causal in MDD pathogenesis rather than merely symptomatic.
Conclusions
Emerging chronotherapeutic approaches, such as light therapy, sleep interventions, and targeted pharmacology, show significant potential for improving depressive symptoms. Personalized circadian-based treatments, guided by genetic and molecular markers, could transform MDD care. Advancing our understanding of the circadian-depression connection offers a promising path to revolutionizing treatment strategies.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Depression. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.